Evidence map›Paper›PMID 33926468›Full record

ArticleJournal of nanobiotechnology2021

A heparin-rosuvastatin-loaded P(LLA-CL) nanofiber-covered stent inhibits inflammatory smooth-muscle cell viability to reduce in-stent stenosis and thrombosis.

Yingjun Liu, Peixi Liu, Yaying Song, Sichen Li, Yuan Shi, Kai Quan, Guo Yu, Peiliang Li, Qingzhu An, Wei Zhu

Open access · goldAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 35 citations in OpenAlex.

  1. [Treatment strategy for severe radiation-induced ulcers near major blood vessels].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2025
    Observational
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Yingjun Liu *Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Peixi Liu *Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Yaying Song *Department of Neurology, Renji Hospital of Shanghai Jiao Tong University, Shanghai, China.
Sichen LiDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Yuan ShiDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Kai QuanDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Guo YuDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.
Peiliang LiDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China. peiliangli@126.com.
Qingzhu AnDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China. anqingzhu@me.com.
Wei ZhuDepartment of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China. drzhuwei@fudan.edu.cn.ORCID http://orcid.org/0000-0001-7190-7476
Fudan University · CNShanghai Jiao Tong University · CNShanghai Medical College of Fudan University · CN

Funding

CAMS Innovation Fund for Medical Sciences 2019-I2M-5-008Clinical Research Plan of SHDC SHDC2020CR4033Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy (CN) SHDC2020CR2034BNational Natural Science Foundation of China 81571102National Natural Science Foundation of China 81801148National Natural Science Foundation of China 81870911Shanghai Municipal Science and Technology Major Project 2018SHZDZX01The Outstanding Academic Leaders Program of Shanghai Municipal Commission of Health and Family Planning 2017BR006
6 · The paper itself

Abstract

backgroundAn endovascular covered-stent has unique advantages in treating complex intracranial aneurysms; however, in-stent stenosis and late thrombosis have become the main factors affecting the efficacy of covered-stent treatment. Smooth-muscle-cell phenotypic modulation plays an important role in late in-stent stenosis and thrombosis. Here, we determined the efficacy of using covered stents loaded with drugs to inhibit smooth-muscle-cell phenotypic modulation and potentially lower the incidence of long-term complications.

methodsNanofiber-covered stents were prepared using coaxial electrospinning, with the core solution prepared with 15% heparin and 20 µM rosuvastatin solution (400: 100 µL), and the shell solution prepared with 120 mg/mL hexafluoroisopropanol. We established a rabbit carotid-artery aneurysm model, which was treated with covered stents. Angiography and histology were performed to evaluate the therapeutic efficacy and incidence rate of in-stent stenosis and thrombosis. Phenotype, function, and inflammatory factors of smooth-muscle cells were studied to explore the mechanism of rosuvastatin action in smooth-muscle cells.

resultHeparin-rosuvastatin-loaded nanofiber scaffold mats inhibited the proliferation of synthetic smooth-muscle cells, and the nanofiber-covered stent effectively treated aneurysms in the absence of notable in-stent stenosis. Additionally, in vitro experiments showed that rosuvastatin inhibited the smooth-muscle-cell phenotypic modulation of platelet-derived growth factor-BB induction and decreased synthetic smooth-muscle-cell viability, as well as secretion of inflammatory cytokines.

conclusionRosuvastatin inhibited the abnormal proliferation of synthetic smooth-muscle cells, and heparin-rosuvastatin-loaded covered stents reduced the incidence of stenosis and late thrombosis, thereby improving the healing rates of stents used for aneurysm treatment.

Indexed as

AnimalsApoptosisCell ProliferationCell SurvivalConstriction, PathologicCytokinesHeparinIntracranial AneurysmMaleMiceMusclesNanofibersPolyestersRabbitsRosuvastatin CalciumStentsCytokinesHeparinPolyesterspoly(lactic acid-co-epsilon-caprolactone)Rosuvastatin CalciumIntracranial aneurysmLate thrombosisLong-term arterial stenosisNanofiber-covered stentRosuvastatin

Identifiers

PMID33926468
PMCPMC8086342
OpenAlexW3159189824

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.